Recent articles
Better Buy: AbbVie vs. Eli Lilly
AbbVie and Eli Lilly are two rock-solid dividend plays, but only one is a buy right now.
Why Biogen Stock Is Crashing Today
Biogen's closely-watched Alzheimer's drug fails to move in the needle in two late-stage trials.
Tilray Should Make This Shocking Business Move Before It's Too Late
Tilray should consider a merger or possibly risk losing its premium valuation.
Does Novavax Have a Viable Path Forward?
Novavax needs a deep-pocketed partner soon.
Why Catalyst Pharmaceuticals Stock Is Popping Today
The drugmaker's Q4 earnings release was a big hit with investors.
3 Stocks to Build Your Portfolio Around
The first stock you ever buy could be the most important. These three names won't disappoint.
Why BioScrip Stock Popped and Then Dropped Today
BioScrip's fourth-quarter results and merger with Option Care Enterprises aren't sitting well with shareholders.
3 Penny Stocks That Could Make You Rich -- or Regretful
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
Why HEXO Stock Briefly Spiked Today
Investors are cheering HEXO's recent acquisition and strong second-quarter results today.
Here's the Real Reason Aurora Cannabis Shares Caught Fire Yesterday
Aurora is hoping to attract a big-time partner to fund its global expansion.
3 Dividend Aristocrats to Buy and Hold Forever
Here's why investors should arguably never sell their shares of AbbVie, PepsiCo, or McDonald's.
Why Verastem Stock Broke Down Today
Verastem's new oncology drug isn't setting the world on fire.
Is Aurora Cannabis the Best Pot Stock to Own Now?
It has built one of the most diverse and far-reaching businesses in the legal marijuana space, but there are some missing pieces in its puzzle.
Why Dynavax Technologies Cratered in February
The biotech's limited cash runway is starting to weigh on its shares.
Why Teva Pharmaceutical Industries Stock Sank in February
Teva's 2019 outlook sent investors packing last month.
Why Intercept Pharmaceuticals Stock Hit the Skids in February
Intercept's NASH data disappointed investors last month.
Why Inovio Pharmaceuticals Stock Broke Down in February
A new debt offering weighed on the biotech's shares last month.
Why Acadia Pharmaceuticals Stock Perked Up in February
The company's comeback story continued to gain momentum last month.
Why Novavax Stock Imploded in February
Novavax's latest clinical failure may prove to difficult to overcome.
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.